CPT codes

53867 CPT codes with hospital pricing data in the network.

• CPT 45U — ONC BRST DUX CARC IS 12 GENE (85 hospitals, — samples)
• CPT 460U — Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes (85 hospitals, — samples)
• CPT 461U — Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes (85 hospitals, — samples)
• CPT 462U — Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary (85 hospitals, — samples)
• CPT 463U — Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial (85 hospitals, — samples)
• CPT 464T — VISUAL EP TEST FOR GLAUCOMA (85 hospitals, — samples)
• CPT 464U — Oncology (colorectal) screening, quantitative real-time target and signal amplification, methylated DNA markers, including LASS4, LRRC4 and PPP2R5C, a reference marker ZDHHC1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as (85 hospitals, — samples)
• CPT 465T — Injection Of Medication Into Space Above Choroid Membrane Of Eye (7 hospitals, — samples)
• CPT 465U — Oncology (urothelial carcinoma), DNA, quantitative methylation-specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative (85 hospitals, — samples)
• CPT 466U — Cardiology (coronary artery disease [CAD]), DNA, genome-wide association studies (564856 single-nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquir (85 hospitals, — samples)
• CPT 467U — Oncology (bladder), DNA, next-generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden (85 hospitals, — samples)
• CPT 468U — Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis (85 hospitals, — samples)
• CPT 469U — Rare diseases (constitutional/heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that (85 hospitals, — samples)
• CPT 46U — FLT3 GENE ITD VARIANTS QUAN (85 hospitals, — samples)
• CPT 470T — Oct Scan Of Skin Lesion With Interpretation And Report, First Lesion (9 hospitals, — samples)
• CPT 470U — Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma (85 hospitals, — samples)
• CPT 471T — Oct Scan Of Skin Lesion With Interpretation And Report, Each Additional Lesion (9 hospitals, — samples)
• CPT 471U — Oncology (colorectal cancer), qualitative real-time PCR of 35 variants of KRAS and NRAS genes (exons 2, 3, 4), formalin-fixed paraffin-embedded (FFPE), predictive, identification of detected mutations (85 hospitals, — samples)
• CPT 472T — PRGRMG IO RTA ELTRD RA (85 hospitals, — samples)
• CPT 472U — Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiqualitative, blood, reported as predictive evidence of early Sjögren's syndrome (85 hospitals, — samples)
• CPT 473T — REPRGRMG IO RTA ELTRD RA (85 hospitals, — samples)
• CPT 473U — Oncology (solid tumor), next-generation sequencing (NGS) of DNA from formalin-fixed paraffin-embedded (FFPE) tissue with comparative sequence analysis from a matched normal specimen (blood or saliva), 648 genes, interrogation for sequence variants, insert (85 hospitals, — samples)
• CPT 474 — Anes prtl rib rescj rad px (91 hospitals, — samples)
• CPT 474T — INSJ AQUEOUS DRG DEV IO RSVR (84 hospitals, — samples)
• CPT 474U — Hereditary pan-cancer (eg, hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next-generation sequencing (NGS (85 hospitals, — samples)
• CPT 475T — Recording Of Fetal Magnetic Heart Signal With Technical Analysis And Interpretation Of Report (7 hospitals, — samples)
• CPT 475U — Hereditary prostate cancer-related disorders, genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation (85 hospitals, — samples)
• CPT 476T — Recording Of Fetal Magnetic Heart Signal With Electronic Signal Transfer Of Data And Storage (7 hospitals, — samples)
• CPT 476U — Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant anal (85 hospitals, — samples)
• CPT 477T — Recording Of Fetal Magnetic Heart Signal With Signal Extraction, Technical Analysis, And Result (7 hospitals, — samples)
• CPT 477U — Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant anal (85 hospitals, — samples)
• CPT 478T — Recording Of Fetal Magnetic Heart Signal With Review And Interpretation Of Report (7 hospitals, — samples)
• CPT 478U — Oncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET) in formalin-fixed paraffin-embedded (FFPE) tissue, interrogation for single-nucleotide variants, insertions/ (85 hospitals, — samples)
• CPT 479T — FXJL ABL LSR 1ST 100 SQ CM (85 hospitals, — samples)
• CPT 479U — Tau, phosphorylated, pTau217 (85 hospitals, — samples)
• CPT 47U — ONC PRST8 MRNA 17 GENE ALG (85 hospitals, — samples)
• CPT 480T — FXJL ABL LSR EA ADDL 100SQCM (85 hospitals, — samples)
• CPT 481T — NJX AUTOL WBC CONCENTRATE (85 hospitals, — samples)
• CPT 481U — IDH1 (isocitrate dehydrogenase 1 [NADP+]), IDH2 (isocitrate dehydrogenase 2 [NADP+]), and TERT (telomerase reverse transcriptase) promoter (eg, central nervous system [CNS] tumors), next-generation sequencing (single-nucleotide variants [SNV], deletions, (85 hospitals, — samples)
• CPT 482U — Obstetrics (preeclampsia), biochemical assay of soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), serum, ratio reported for sFlt-1/PlGF, with risk of progression for preeclampsia with severe features within 2 weeks (85 hospitals, — samples)
• CPT 483T — TMVI PERCUTANEOUS APPROACH (84 hospitals, — samples)
• CPT 483U — Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance (85 hospitals, — samples)
• CPT 484T — TMVI TRANSTHORACIC EXPOSURE (84 hospitals, — samples)
• CPT 484U — Infectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance (85 hospitals, — samples)
• CPT 485T — OCT MID EAR I&R UNILATERAL (84 hospitals, — samples)
• CPT 485U — Oncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy numb (85 hospitals, — samples)
• CPT 486T — OCT MID EAR I&R BILATERAL (84 hospitals, — samples)
• CPT 486U — Oncology (pan-solid tumor), next-generation sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction (85 hospitals, — samples)
• CPT 487T — Biomechanical Mapping Accessed Through The Vagina (7 hospitals, — samples)
• CPT 487U — Oncology (solid tumor), cell-free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidy-corrected gene copy number amplifications and losses, gene rearrangements, and microsatellite instabil (85 hospitals, — samples)